Heena Dodhia’s Post

This weeks blog by my colleagues Rishi Unnikrishnan and Vanessa Parra Ferreira explores the rationale behind biopharma divestiture transactions and how a five-step approach can help ensure the divestiture transaction realises optimal value. A divesture transaction is the process of liquidating assets with the express intention of generating value. and is a critical tool in the corporate growth toolbox. As companies evolve and review their portfolios, boards have long used divestitures as a strategic tool to sell brands or business units that they no longer consider as part of their core business. The cash proceedings are then invested in assets and services that are more closely aligned with their business growth strategy. In the biopharma industry, the number of divestments has increased dramatically over the past two years and while debate has historically been focused on mergers and acquisitions, divestitures are fast becoming a critical part of biopharma's growth strategy. Emily May John Haughey Colin Terry James Gregson Heena Dodhia Amar Shah Márcia Costa Shreya Nagpal Gillian W. Nicola Abernethy Jennifer Del Carlo

Projected returns on pharma R&D have increased to 4.1%, a significant rise from last year’s figure of 1.2%. 📈 Find out what’s driving this increase in the latest edition of our annual R&D ROI report 📃, ‘Unleash AI’s potential’: https://deloi.tt/49O5Tr0 #DeloitteUKLSHC #DeloitteRDROI23 #RandD #Lifesciences #AI

Join me for this Deloitte Academy event where we will be sharing insights from our latest ‘Measuring the return from #pharmaceutical innovation’ report with our expert panel including Paula Gildert, formerly from Takeda and Matt Hefner, Pfizer. We will also discuss how pharma leaders can improve their R&D productivity for clinical trials, utilise #AI and technological innovations and reduce costs alongside M&A. Register to attend online using the link below or contact me directly if you’d like to attend in person in our London offices with our team. https://bit.ly/3VZNc0f #DeloitteUKLSHC #DeloitteRDROI23 Paula Gildert Matthew Hefner Kevin Dondarski Naveed Panjwani Karen Taylor Emily May Andrew Bolt Julian Remnant

I’m pleased to say that we’ve just published Deloitte’s Women’s Health Cost Gap in the UK! 📢   It includes a YouGov survey of 3,156 adults and some very interesting insights into the ‘health cost gap’ affecting women and attitudes towards workplaces offering women’s health benefits. 🚺   Did you know:    💊 Working women, on average, are spending £100 more on health related expenses than men - this adds up to over £1.5bn more when you put together all the working women in the UK; 💊 Out of the women surveyed 52% said they made extra out-of-pocket expenses on health per year, versus only 39% of men; 💊 60% of women said they are more attracted to join companies which invest in women’s health benefits for their workforce, and this is even more true for younger women.   How do we address this? 👉 we need a collaborative approach – investors, healthcare providers, policy makers, life sciences companies and employers all need to take action.   Simply put - supporting women’s health is not only important for society, but a sound investment in the future of the workforce and overall economy.   Read the full report here: https://lnkd.in/evVUEvN3   #Womenshealth #HealthEquity #ZeroHealthGaps #DeloitteHealthEquityInstitute Sara Siegel John Haughey Greg Reh Vicky Levy Jay Bhatt Andrew Davis Karen Taylor Stephanie Delanbanque, PhD Zara King Patsy Bolduc Laura Parsons Imran Choudhury Gillian W. Maria João Cruz, PhD Márcia Costa Karen Kirkham Cosima Pettinicchio Martha Kirk Victoria Katzer Emily May Terry Koch Caitlin Gorman Rekha Jacob Burçak Aydın Patricia Gee Aida Demneri Claire Burton Oriana Kraft Bridget Gorham

As stakeholders demand more than just financial gains, it's crucial for investors to consider social and environmental responsibility when it comes to private equity. Deloitte's PE Index, launched today, analyses the performance of 92 PE-backed businesses in the consumer sector across three key dimensions: people, planet, and profit. This report provides insights on how private equity can lead the charge towards a more sustainable future, while also delivering financial returns. Check it out now! https://lnkd.in/exFZH7Md #PEIndex #sustainability #responsibleinvesting

I spent a lifetime working in Consumer Health, a joyful and adorable one. With a passion for M&A, I was involved in a number of deals. Not ever I was more excited than now to have this expertise: this critical sector leading the world to a healthier place is prone to consolidation, and a series of deals are to be expected. I just wrote this "blog post" laying out the hypothesis and implications of a potential consolidation. I'm super keen to hear the views of this network - thoughts to share? #m&a #consumerhealth #otc https://lnkd.in/ekH6e6s3